Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study) [PDF]
Kidney MedicineRationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab, a complement C5 inhibitor (C5i), is approved for aHUS; however, published evidence in
Ramy Magdy Hanna +8 more
doaj +2 more sources
Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report [PDF]
BMJ Neurology OpenBackground Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system (CNS). Management during pregnancy is challenging due to limited safety data for disease-modifying therapies.Case presentation ...
Anu Jacob +3 more
doaj +2 more sources
Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice [PDF]
Frontiers in NeurologyPurposeTo describe the early experience of ravulizumab use in acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ve gMG).MethodsThis multicenter retrospective study included AChR+ve gMG patients who were treated with ravulizumab
Nakul Katyal +4 more
doaj +3 more sources
Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database [PDF]
Frontiers in ImmunologyBackgroundRavulizumab is a long-acting C5 complement inhibitor that provides sustained suppression of the complement pathway. It is currently approved by the US Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis ...
Yue Zhou +3 more
doaj +2 more sources
Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. [PDF]
PLoS ONEIntroductionComplement component 5 inhibitor therapies (C5ITs) for rare hematological, renal, and neurological diseases are associated with increased meningococcal infection risk. Robust risk mitigation measures include vaccination, drug safety programs,
Cynthia Carrillo Infante +1 more
doaj +2 more sources
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature [PDF]
Frontiers in Immunology, 2023 Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease characterized by complement-mediated intravascular hemolysis, thrombosis, and bone marrow failure. Eculizumab and ravulizumab are anti-C5 monoclonal antibodies
Nicole Galli +11 more
doaj +3 more sources
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome [PDF]
Drugs, 2021 Ravulizumab (Ultomiris®), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has been re-engineered from eculizumab to extend its terminal elimination half-life, resulting in a more ...
exaly +3 more sources
Kidney MedicineRationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes
Bradley P Dixon +2 more
exaly +3 more sources
Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report [PDF]
Frontiers in ImmunologyIntroductionNeuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system often associated with aquaporin-4-immunoglobulin-G (AQP4-IgG), which activate the complement system, and it can lead to progressive ...
Andrea Neundorf, Ralf Dittrich
doaj +2 more sources
Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis [PDF]
Journal of Health Economics and Outcomes Research# Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder with C5 inhibitors (C5i), eculizumab and ravulizumab, being part of current treatment options.
Srinivas K Tantravahi +9 more
doaj +2 more sources